There were no differences between the treatment groups for additional secondary end points , for individual components of the primary end point , or in all-cause mortality ( @ events in the darapladib group and @ in the placebo group -LSB- @ % vs @ % at @ years ; HR , @ -LSB- @ % CI , @-@ @ -RSB- ; P = @ ) .